checkAd

    EQS-News  166  0 Kommentare Carl Zeiss Meditec remains on growth course in fiscal year 2021/22

    EQS-News: Carl Zeiss Meditec AG / Key word(s): Annual Results/Annual Report
    Carl Zeiss Meditec remains on growth course in fiscal year 2021/22

    09.12.2022 / 07:00 CET/CEST
    The issuer is solely responsible for the content of this announcement.


     
    Carl Zeiss Meditec remains on growth course in fiscal year 2021/22
     
    High revenue and strong order situation in spite of persistent geopolitical and macroeconomic risks

     

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Carl Zeiss Meditec AG!
    Long
    91,14€
    Basispreis
    0,81
    Ask
    × 12,24
    Hebel
    Short
    105,63€
    Basispreis
    0,82
    Ask
    × 12,09
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    JENA, 9 December 2022

     

    Carl Zeiss Meditec generated revenue of around €1,903m in fiscal year 2021/22 (prior year: €1,647m), corresponding to growth of +15.5% (adjusted for currency effects: +13.3%). Orders received increased even more significantly to around €2,251m (+30.1%, adjusted for currency effects: +27.7%). Earnings before interest and taxes (EBIT) increased to around €397m (prior year: €374m). The EBIT margin was 20.9% (prior year: 22.7%).

    Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG: “Once again, we are looking back on a very successful fiscal year. Given the heightened geopolitical and macroeconomic risks and the rising inflation rate, we are extremely satisfied with the result achieved. Due to the well filled order books and steady demand for our innovations, we are confident that we will remain on a growth course in 2022/23.”

    Both strategic business units contribute to growth

    Revenue in the strategic business unit (SBU) Ophthalmic Devices increased by +17.0% in fiscal year 2021/22 (adjusted for currency effects: +15.0%), to €1,469m (prior year: €1,256m). In particular the business with recurring revenue from consumables, implants and services made a significant contribution to this growth. Orders received increased from €1,319m to €1,721m, an increase of +30.5% (adjusted for currency effects: +28.3%). In addition to robust demand in the equipment and consumables business, this is also attributable to the increase in production and delivery time in the equipment business due to shortages in the global supply chains and materials procurement.

    Seite 1 von 5


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Carl Zeiss Meditec remains on growth course in fiscal year 2021/22 EQS-News: Carl Zeiss Meditec AG / Key word(s): Annual Results/Annual Report Carl Zeiss Meditec remains on growth course in fiscal year 2021/22 09.12.2022 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement.   …

    Schreibe Deinen Kommentar

    Disclaimer